BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

680 related articles for article (PubMed ID: 16885699)

  • 21. Drug insight: aminosalicylates for the treatment of IBD.
    Nielsen OH; Munck LK
    Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Chronic inflammatory bowel diseases. Update on evidence-based therapy].
    MMW Fortschr Med; 2005 Apr; 147(17):58-9. PubMed ID: 15903063
    [No Abstract]   [Full Text] [Related]  

  • 23. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.
    Mulder CJ; van den Hazel SJ
    Mediators Inflamm; 1998; 7(3):135-6. PubMed ID: 9705596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. New oral salicylates in the therapy of chronic idiopathic inflammatory bowel disease.
    Robinson MG
    Gastroenterol Clin North Am; 1989 Mar; 18(1):43-50. PubMed ID: 2646221
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [5-aminosalicylic acid in the treatment of ulcerative colitis and Crohn's disease].
    Moum B
    Tidsskr Nor Laegeforen; 2003 Sep; 123(18):2565-7. PubMed ID: 14714043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-Aminosalicylic acid containing drugs. Delivery, fate, and possible clinical implications in man.
    Christensen LA
    Dan Med Bull; 2000 Feb; 47(1):20-41. PubMed ID: 10709142
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral 5-ASA therapy in ulcerative colitis: what are the implications of the new formulations?
    Sandborn WJ
    J Clin Gastroenterol; 2008 Apr; 42(4):338-44. PubMed ID: 18277908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pharmacological bases of therapy with 5-ASA].
    Beltrán B; Martínez-Cuesta MA; Calatayud S; Hinojosa J; Esplugues JV
    Gastroenterol Hepatol; 1997; 20(6):322-34. PubMed ID: 9296850
    [No Abstract]   [Full Text] [Related]  

  • 29. 5-ASA enema therapy.
    Hanauer SB
    Neth J Med; 1989 Jun; 35 Suppl 1():S11-20. PubMed ID: 2702307
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mesalamine once daily is more effective than twice daily in patients with quiescent ulcerative colitis.
    Dignass AU; Bokemeyer B; Adamek H; Mross M; Vinter-Jensen L; Börner N; Silvennoinen J; Tan G; Pool MO; Stijnen T; Dietel P; Klugmann T; Vermeire S; Bhatt A; Veerman H
    Clin Gastroenterol Hepatol; 2009 Jul; 7(7):762-9. PubMed ID: 19375519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pancreatitis in inflammatory bowel diseases.
    Pitchumoni CS; Rubin A; Das K
    J Clin Gastroenterol; 2010 Apr; 44(4):246-53. PubMed ID: 20087199
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 5-ASA enema versus oral sulphasalazine in maintaining remission in ulcerative colitis.
    Andreoli A; Spinella S; Levenstein S; Prantera C
    Ital J Gastroenterol; 1994 Apr; 26(3):121-5. PubMed ID: 7914759
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mesalamine restores angiogenic balance in experimental ulcerative colitis by reducing expression of endostatin and angiostatin: novel molecular mechanism for therapeutic action of mesalamine.
    Deng X; Tolstanova G; Khomenko T; Chen L; Tarnawski A; Szabo S; Sandor Z
    J Pharmacol Exp Ther; 2009 Dec; 331(3):1071-8. PubMed ID: 19762547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Use of mesalazine in diverticular disease.
    Di Mario F; Comparato G; Fanigliulo L; Aragona G; Cavallaro LG; Cavestro GM; Franzé A
    J Clin Gastroenterol; 2006 Aug; 40 Suppl 3():S155-9. PubMed ID: 16885700
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of 5-aminosalicyltaurine as a colon-specific prodrug of 5-aminosalicylic acid for treatment of experimental colitis.
    Jung Y; Kim HH; Kim H; Kong H; Choi B; Yang Y; Kim Y
    Eur J Pharm Sci; 2006 May; 28(1-2):26-33. PubMed ID: 16455235
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does treatment schedule matter? Once daily versus divided doses of 5-ASAs.
    Kane S
    Dig Dis; 2010; 28(3):478-82. PubMed ID: 20926875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. MMX mesalamine.
    Baker DE
    Rev Gastroenterol Disord; 2006; 6(3):146-52. PubMed ID: 16957657
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Review article: induction therapy for patients with active ulcerative colitis.
    Travis SP
    Aliment Pharmacol Ther; 2006 Sep; 24 Suppl 1():10-6. PubMed ID: 16939424
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of 5-aminosalicylic acid therapy for maintenance of remission in ulcerative colitis.
    Yen EF; Kane SV; Ladabaum U
    Am J Gastroenterol; 2008 Dec; 103(12):3094-105. PubMed ID: 18775007
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mesalamine with MMX technology for the treatment of ulcerative colitis.
    Schreiber S; Kamm MA; Lichtenstein GR
    Expert Rev Gastroenterol Hepatol; 2008 Jun; 2(3):299-314. PubMed ID: 19072380
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.